

AMENDMENTS TO THE CLAIMS

Claims 1-55 (canceled)

Claim 56 (previously presented): A method to ameliorate a side effect of anti-neoplasia treatment in a subject, wherein said side effect is mucositis, which subject is undergoing treatment with an antineoplasia agent, which method comprises administering to said subject a pharmaceutical composition comprising muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) encapsulated in multilamellar liposomes.

Claims 57-60 (canceled)

Claim 61 (currently amended): A method to ameliorate a side effect of anti-neoplasia treatment in a subject, wherein said side effect is mucositis, which subject has been treated with an anti-neoplasia agent, which method comprises administering to said subject a pharmaceutical composition comprising muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) encapsulated in multilamellar liposomes, whereby administration of MTP-PE ameliorates mucositis.